Agoracom Blog

Applied BioSciences $APPB – Reports Second Quarter Fiscal Year 2020 Financial Results and Outlines Corporate Strategy $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 8:45 AM on Friday, November 15th, 2019
  • Successfully building BioPharma pipeline in high-value indications
  • Company plans to advance IND-cleared program into a Phase 1 study in a metabolic disease indication in early 2020
  • Strategic corporate shift to fully focus on BioPharma Division unlocks opportunities for non-dilutive capital to fund pipeline

Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), today announced its financial results for the second quarter Fiscal Year 2020 ended September 30, 2019. The Company also provided an update on its corporate and clinical progress.

“We continue to push forward on all fronts as we work to establish Applied as a leader in the development and commercialization of novel, science-driven, synthetic endocannabinoid therapeutics / biopharmaceuticals and impact areas of significant unmet need,” commented Dr. Raymond Urbanski, Chief Executive Officer of Applied. “Over the course of the past quarter, we have made notable strides on the corporate and clinical front and remain diligent in working to drive value for all stakeholders.”

“We continued to build out our BioPharma division and have established a Scientific Advisory Board of leading experts in the endocannabinoid space. We were pleased to have welcomed our inaugural members Judith Korner, M.D. and Patricia Reggio, Ph.D., who will play an integral role as we look to optimize our therapeutic pipeline and look to make additional appointments in the near term to help drive this business unit forward. Additionally, we have continued to execute on our robust business development initiatives and remain in late-stage discussions to in-license our product candidates that we believe have the potential to address a number of areas with significant unmet need. In tandem, we continue to remain opportunistic in accessing the necessary non-dilutive funding and capital through strategic investments from which we believe will provide us with the foundation and momentum to move forward.”

Applied BioPharma: developing science-driven synthetic cannabinoid therapeutics that satisfy unmet medical needs and continue to drive innovation in the endocannabinoid space.

The Applied BioPharma division is focused on the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS).

Applied Biopharma has to date developed partnerships with leading academic and research institutions and has exclusively licensed patented, synthetically derived small molecule candidates which target the ECS G-protein coupled receptors (GPCRs) e.g., the cannabinoid receptor 1 and cannabinoid receptor 2, for the treatment of metabolic diseases (type 2 diabetes, obesity, fatty liver disease) and inflammation (pulmonary inflammation, optic nerve inflammation following traumatic brain injury and ischemic/reperfusion injury such as acute kidney injury post-transplant and acute myocardial infarction (heart attack).

The Company’s growing pipeline is comprised of selective CB1 and CB2 agonist, inverse agonist and antagonists utilizing multiple scaffolds and state-of-the-art medicinal chemistry across several academic centers and institutions.

  • Applied expects to advance the first of its preclinical programs into open INDs in 2020.
    • ABP-1902, its lead CB2 agonist, intended for mitigating the deleterious effects of ischemic-reperfusion injury.
    • ABP-1901, its lead CB2 inverse agonist, which has demonstrated effectiveness in limiting or reversing damage due to neuroinflammation.
  • Applied expects to advance the first of its clinical programs into a Phase 1 study in early to mid-2020.

The Company is actively advancing and seeking additional in-license opportunities with the goal of developing an industry-leading pipeline of endocannabinoid system-targeted drug candidates that address significant unmet needs across a wide range of therapeutic areas.

Applied Products: portfolio of consumer, animal health, women’s health and sports medicine of hemp-derived, THC-free, pharmaceutical grade CBD isolates and distribution products, all of which ship to the majority of U.S., as well as to multiple non-U.S. countries.

The Applied Products business unit is focused on maximizing top-line revenue through selective investments in product lines and marketing campaigns (increase share-of-voice), continually reevaluating the endocannabinoid Health & Wellness environment for opportunities and developing and implementing a nutraceutical strategy.

Applied Products has seen a modest year-over-year increase in top line revenue. At this time the Board, with the understanding that to be successful in the lucrative yet dynamic and very competitive consumer CBD space would require significant resource and capital allocations, is evaluating various strategic options for this business unit.

Trace Analytics, Inc: Applied’s majority owned subsidiary scalable analytics cannabis/cannabinoid laboratory poised to meet the demands for mandated regulatory cannabis/cannabinoid testing.

In July 2019, Trace Analytics was contracted for services with the Washington State Department of Agriculture (WSDA). This contract includes testing Industrial Hemp samples and include percentage testing for post-decarboxylation delta 9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid (THC-A) to ensure the percentages of certain cannabinoids are below Federal limits.

Applied is currently in late-stage discussions for a strategic transaction, expected to close by year end.

Upcoming Milestones Expected to Drive Value

  • Finalize the in-licensing of product candidates to build pipeline for the Applied BioPharma division.
  • Closing on the sale of Trace Analytics leading to the infusion of non-dilutive capital into the company.
  • Finalize and execute on the strategic options for Applied Products.
  • Successfully execute overall strategy of the Company and business development efforts.
  • Engage with key stakeholders in the investment community and execute on the robust effort to raise awareness of the Company.
  • Uplist to a National Exchange.

Summary of Financial Results for Second Quarter FY2020 Ended September 30, 2019

For the quarter ended September 30, 2019, the Company reported net loss of approximately $777,746 or net loss per diluted share of $0.06, compared to a net loss of approximately $110,423 or a net loss per diluted share of $0.01, for the quarter ended September 30, 2018.

The Company reported revenues from Applied BioSciences’ CBD product lines was $169,654 and $59,400 during the six months ended September 30, 2019 and 2018, respectively. The increase reflects higher sales across all of the Company’s CBD brand product lines, most notably in its topical products, combined with expansion into sales of bulk hemp seed and raw CBD. Service revenue resulting from the Company’s lab testing is attributed solely to the acquisition of Trace Analytics in January 2019, and totaled $286,077 for the six months ended September 30, 2019.

General and administrative expenses increased $519,140 to $707,192 for the three months ended September 30, 2019 as compared to $188,052 for the three months ended September 30, 2018. The increase was mainly attributable to the acquisition of Trace Analytics and addition of our Applied BioPharma subsidiary, with general and administrative expenses for the remainder of the Company.

The Company ended the quarter with $73,412 in cash and cash equivalents. The Company is actively evaluating opportunities to fund continued growth in its products and services revenue along with planned business development activities for Applied BioPharma and anticipates closing a financing by the end of first quarter Fiscal Year 2020.

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. We also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Applied BioSciences | Comments Off on Applied BioSciences $APPB – Reports Second Quarter Fiscal Year 2020 Financial Results and Outlines Corporate Strategy $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

CardioComm Solutions $EKG.ca – #Mhealth Solutions Market Forecasting CAGR of 34.34% $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 4:33 PM on Thursday, November 14th, 2019

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

mHealth Solutions Market Forecasting CAGR of 34.34%

  • mHealth solutions market is expected to rise from its initial estimated value of USD 28.06 billion in 2018 to a projected value of USD 297.70 billion by 2026, registering a CAGR of 34.34% in the forecast period of 2019-2026
  • This rise in market value can be attributed to lower physician ratio as compared to patients requiring healthcare provisions.

Market Definition: Global mHealth Solutions Market

mHealth solutions can be defined as the technology utilized in providing healthcare services and products through smart devices and smart phones. This technology is used for collecting patient data, their patient history and also through this technology, healthcare providers can ease their workflow helping them work in a systematic and effective way.

Key Market Competitors: Global mHealth Solutions Market

Medtronic; Cerner Corporation; Koninklijke Philips N.V.; ZTE Corporation; Nokia; AirStrip Technologies; BioTelemetry, Inc.; Apple Inc.; iHealth Labs Inc.; athenahealth, Inc.; AliveCor, Inc.; Zebra Technologies Corp; Johnson & Johnson Services, Inc.; Cisco; AT&T Intellectual Property; AgaMatrix; OMRON Corporation; Withings and Qualcomm Technologies, Inc. are few of the major competitors currently working in the mHealth solutions market.

Market Drivers:

  • Growth in adoption and usage of smart devices and smart phones in healthcare and medical monitoring; this factor is expected to act as a driver for the market growth
  • Increasing focus on patient-focused and individual specific healthcare provisions; this factor is expected to drive the market growth

Market Restraints:

  • Absence of any regulations and standardization in the market restraining the market growth
  • Lack of enthusiasm in providing information regarding the identification of correct mHealth applications and solutions; this factor is expected to restrain the market growth

Key Developments in the Market:

  • In January 2019, Zebra Technologies Corp announced that they are planning to launch “DS1800-HC” collection of scanners and “TC51-HC” cellular PC for healthcare professionals in India. These products will assist physicians in easing their workflow resulting in increased productivity and effectiveness.
  • In March 2016, ZTE Corporation announced the launch of all-in-one mHealth product that utilizes a number of smart devices and incorporates IoT technology in identifying the diseases & disorders and providing patient specific medical care.

Global mHealth solutions market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of mHealth solutions market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Source: https://weeklyspy.com/2019/11/14/mhealth-solutions-market-forecasting-cagr-of-34-34-with-nokia-jawbone-ihealth-labs-cisco-athenahealth-alivecor-inc-omron-healthcare-inc-agamatrix/

Tags: , , , , ,
Posted in CardioComm Solutions | Comments Off on CardioComm Solutions $EKG.ca – #Mhealth Solutions Market Forecasting CAGR of 34.34% $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

BetterU Education Corp. $BTRU.ca – #Samsung – Backed #TagHive Enters #India To Digitise Public Schools With #Edtech Device And Platform $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 3:27 PM on Thursday, November 14th, 2019
SPONSOR:  BetterU Education Corp. aims to provide access to quality education from around the world. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated ecosystem. Click here for more information.

Samsung-Backed TagHive Enters India To Digitise Public Schools With Edtech Device And Platform

  • TagHive has launched Class Sathi in two Madhya Pradesh districts
  • The startup was a part of Samsung’s C-lab incubator programme
  • TagHive aims to bring affordable digital learning to primary schools in rural India

In the Indian context, the education infrastructure and quality of learning has always come under scrutiny, especially due to concerns of outdated syllabi and teaching methods at the primary level in public schools.

Most edtech startups in India are looking to solve this by bringing learning to the mobile phone or PC, but that’s not always possible at schools in smaller towns and villages, which do not have the wherewithal to implement such high-tech solutions. That’s what TagHive is looking to overcome with its affordable edtech platform (device and software) for the Indian public and primary school market.

Suwon, South Korea-based TagHive has launched its flagship product Class Saathi in two districts of Madhya Pradesh. Tying up with the state government, TagHive’s Class Saathi mobile clicker solution and the companion app will be available across 13 schools in its two districts.

Founded in 2017 by IIT and Harvard alumni, Pankaj Agarwal, the startup for his innovation in the education segment has received funds from Samsung Ventures and Enlight Ventures. The startup was also incubated by Samsung’s internal C-Lab programme after the South Korean chaebol discovered Agarwal’s idea during his stint at the company.

Speaking to Inc42, the founder said that Samsung C-Lab supported TagHive with the necessary resources such as funding, workspace, technical support and culture-building through the incubation programme. “After 15 months of working on my idea at Samsung, it was chosen to be spun off as an independent company, TagHive. Samsung Ventures has put in seed capital of over INR 2.5 Cr,” Agarwal said.

The AI-powered classroom engagement solution Class Saathi aims to make tech-based learning accessible and affordable for schools in rural India with little or no infrastructural investments. The startup also aims to increase student participation and learning outcomes, while at the same time supporting and motivating teachers to improve their teaching methodology.

TagHive doesn’t just limit itself to teachers and students but also involves another key stakeholder in the education chain — the child’s parents. Agarwal said that this helps keep everyone in the loop about the student’s progress.

Source: https://inc42.com/buzz/samsung-backed-taghive-enters-india-to-digitise-public-schools-with-edtech-device-and-platform/

Tags: , , , , , ,
Posted in betterU Education Corp | Comments Off on BetterU Education Corp. $BTRU.ca – #Samsung – Backed #TagHive Enters #India To Digitise Public Schools With #Edtech Device And Platform $ARCL $CPLA $BPI $FC.ca

Applied BioSciences $APPB – New, Online Resource Designed to Assist Pharmacists With CBD Products $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 2:30 PM on Thursday, November 14th, 2019

SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics. As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info

The National Community Pharmacists Association (NCPA) has launched a new resource for pharmacists looking to understand and purchase reliable cannabidiol (CBD) products, called the NCPA CBD Source.

The online resource features CBD products that have been tested for concentrations of all cannabinoids, including CBD and tetrahydrocannabinol (THC), by an independent, third-party lab. The site also features experts that pharmacists can contact with questions regarding buying, selling, and marketing. In addition, pharmacists will be able to evaluate each company included in the resource, as well as see each company’s products.

CBD products have exploded in recent months following the Hemp Farming Act of 2018, which removed hemp from the list of Schedule I controlled substances. According to a statement from NCPA, the United States CBD industry grew by nearly 40% in 2017, and is expected to reach $22 billion by 2024.

CBD can help relieve pain and inflammation resulting from chronic illnesses, as well as boost the immune system, and these effects have led to a flood of patient interest.

“Many pharmacies are deciding to sell CBD products because of the patient demand and because, as the medication expert, they can serve as the source of truth,” said NCPA CEO B. Douglas Hoey, RPh, MBA.

Carter High, PharmD, of Best Value Rhome Pharmacy, said he plans on using the service to bolster the knowledge and products that he already trusts. CBD products are new to the pharmacy wheelhouse, High said, and he gets many phone calls with sales pitches from various CBD companies.

“It gets a little confusing as to whether or not they’re just talking a really good sales pitch, or if they really do have a genuine product,” High said.

High said it’s important for pharmacists to make sure they understand the uses and mechanisms of CBD products, but that this can be challenging given the crowded marketplace.

“Understanding just how CBD affects the body is a very good avenue for a pharmacist to delineate themselves as a knowledge expert on a new upcoming way of how to help patients out,” High said. “A marketplace such as [NCPA CBD Source] fills a very big gap that was missing, and helps from an efficiency standpoint at the store level.”

While he is excited to use the resources provided, High did emphasize that it doesn’t relieve pharmacists of the responsibility to ensure that the products are reliable, safe, and right for each patient. It does, however, help reassure pharmacists that the decisions they are making are the right ones, he added.

REFERENCE

NCPA, PRS Launch First-of-its-Kind “CBD Source” Tool for Pharmacists

https://www.ncpanet.org/newsroom/news-releases/2019/10/29/ncpa-prs-launch-first-of-its-kind-cbd-source-tool-for-pharmacists.

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Applied BioSciences | Comments Off on Applied BioSciences $APPB – New, Online Resource Designed to Assist Pharmacists With CBD Products $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Empower Clinics $CBDT.ca – The case for treating #PTSD with #cannabis $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 1:55 PM on Thursday, November 14th, 2019

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics
  • Patient database of over 165,000 patients 
  • Platform generating $4MM USD in revenue annually (2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Launching CBD extraction facility
  • First extraction system capacity = 6,000 Kg per year.

The case for treating PTSD with cannabis

  • Previous research has linked cannabis use with poorer mental health in PTSD patients, but it’s unclear whether cannabis exacerbates PTSD symptoms, or if patients with worse symptoms are simply self-medicating more.
  • Much of he existing evidence for cannabis as a PTSD treatment comes from patient reports of success.

Research shows that cannabis use by people living with post-traumatic stress disorder may reduce their likelihood of depression and suicide

Stock photo This article, written by Stephanie Lake, University of British Columbia and M-J Milloy, University of British Columbia, originally appeared on The Conversation and has been republished here with permission:

Post-traumatic stress disorder (PTSD), a psychiatric condition linked to surviving or witnessing a traumatic life event, will affect around one in 10 Canadians at some point in their lives. PTSD can cause agitation, flashbacks, impaired concentration and memory, insomnia and nightmares and these symptoms can increase the risk of substance abuse and dependence, depression and suicide.

Many patients struggle to find adequate symptom relief from conventional treatments for PTSD including anti-depressant or anti-psychotic medications and psychological treatments such as trauma-focused cognitive behavioural therapy.

Unsurprisingly, many turn to alternative ways of coping — such as medical cannabis use. This is especially evident in the dramatic rise in number of Canadian military veterans receiving government reimbursement for medical cannabis, with PTSD as a common reason for use.

The results of clinical trials testing cannabis as a PTSD treatment are pending. Previous research has linked cannabis use with poorer mental health in PTSD patients, but it’s unclear whether cannabis exacerbates PTSD symptoms, or if patients with worse symptoms are simply self-medicating more. Much of the existing evidence for cannabis as a PTSD treatment comes from patient reports of success.

As epidemiologists and substance use researchers, we have been exploring the relationship between cannabis and PTSD using readily available Statistics Canada mental health data.

In a recent study, published in the Journal of Psychopharmacology, we found that PTSD increased the risk of major depressive episodes among Canadians who didn’t use cannabis by roughly seven times, and suicidal ideation by roughly five times. But, among Canadians who did use cannabis, PTSD was not statistically associated with either outcome.

How cannabis works in the body

Substance use, including cannabis use, is common among trauma survivors. It’s easy to write off the drug as just a tool to briefly escape negative feelings, at the risk of worsening longer-term symptoms. However, the relationship between cannabis and PTSD is more complex than it appears on the surface.

Our bodies naturally produce molecules called endogenous cannabinoids that fit into special cannabinoid receptors throughout the brain and body. This endocannabinoid system is involved in stabilizing bodily processes, including regulating many functions of the brain that tend to be affected after traumatic experiences, such as fear, memory and sleep.

Certain components of the cannabis plant, including the well-known molecules tetrahydrocannabinol (THC, the component of cannabis that produces the high) and cannabidiol (CBD, the component of cannabis that won’t get you high, but has potential for treating epilepsy, inflammation, nausea and anxiety) are also cannabinoids because of their structural similarity to endogenous cannabinoids.

Even though THC and CBD aren’t naturally produced in our bodies, they can interact with the endocannabinoid system to influence a number of biological processes.

Research is still uncovering if and how cannabis works within the body to affect the course of PTSD. Brain imaging research suggests that patients with PTSD have an abundance of cannabinoid receptors but produce few endogenous cannabinoids to lock into them, meaning that supplementing the body with plant-based cannabinoids like THC might help some brain processes function as normal.

Reduced depression and suicide

Roughly one in four individuals with PTSD in the Statistics Canada survey data that we analyzed used cannabis, compared to about one in nine in the general population.

In our study, we used statistical models to quantify the relationship between having PTSD and recently experiencing a major depressive episode or suicidal ideation. We hypothesized that if cannabis helped mitigate symptoms of PTSD, we’d see a much weaker association between PTSD and these indicators of mental distress in the cannabis-using population.

Indeed, exploring the associations in this way while controlling for other factors (such as sex, age, income, other substance use, other mental health problems) supported our hypothesis.

In a follow-up analysis of the 420 individuals in the sample who had PTSD, we categorised cannabis use into “no use,” “low-risk use” and “high-risk use” (meaning that they screened positive for cannabis abuse or dependence).

We found that low-risk cannabis users were actually less likely than non-users to develop a major depressive episode or to be suicidal, though there was a trend towards increased risk of both outcomes for the high-risk users.

A promising new signal

People with PTSD are more likely to experience depression and suicidal ideation. However, our findings suggested that these indicators of mental health were improved when they were engaging in lower-risk cannabis use.

Our study has a number of limitations that prevent us from being able to understand whether cannabis is what’s causing the reduced association between PTSD, depression and suicide.

For example, our data captures information covering participants’ experiences from the previous year, meaning we can’t actually decipher what came first: the cannabis use, the PTSD or the major psychological episodes.

We didn’t have detailed information about how participants used cannabis: for example, the type and dose of cannabis they used, how often they used it or how they consumed it. These details will be crucial to future research in this area.

Our study’s strength comes from its ability to describe patterns of PTSD symptoms and cannabis use in a large sample that’s considered to be representative of the Canadian population. Although our findings suggest that cannabis could be of possible therapeutic use in the treatment of PTSD, cannabis use is not without risks, including the development of cannabis use disorder.

We’ve uncovered a promising new signal on the potential of cannabis-based therapies, but we look forward to much work ahead in understanding how they might fit into PTSD and mental health treatment more broadly.

Source: https://www.collingwoodtoday.ca/local-news/canada-the-case-for-treating-ptsd-with-cannabis-1831760

Tags: , , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca – The case for treating #PTSD with #cannabis $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

New Age Metals $NAM.ca – Sales Revenue of #Palladium to Soar in the Near Future Owing to Growing Consumer Adoption $WG.ca $XTM.ca $WM.ca $PDL.ca

Posted by AGORACOM-JC at 12:59 PM on Thursday, November 14th, 2019

SPONSOR: New Age Metals Inc. The company’s Lithium Division has already made significant acquisitions in Canada and the USA. The company also owns one of North America’s largest primary platinum group metals deposit in Sudbury, Canada. Updated NI 43-101 Mineral Resource Estimate 2,867,000 PdEq Measured and Indicated Ounces, with an additional 1,059,000 PdEq Ounces in the Inferred. Learn More.

Sales Revenue of Palladium to Soar in the Near Future Owing to Growing Consumer Adoption

  • Global market for palladium is likely to experience significant growth with declining demand for metals and increasing demand for recycling metals, leading to palladium demand outstripping the supply.
  • In addition, changing prospects of investments in palladium have also contributed to the growth of the market

By: PMR Research

Palladium is a lustrous silvery-white rare metal used in a diverse range of applications. The metal with other elements such as osmium, iridium, ruthenium, rhodium, and platinum are referred to as Platinum Group Metals (PGM). Palladium is majorly consumed in the automotive industry as catalytic converters, manufacturing of electronics and jewelry, as well as chemical and dental applications. Palladium is sourced from two major sources, viz., mine production and recycling.

The global market for palladium is likely to experience significant growth with declining demand for metals and increasing demand for recycling metals, leading to palladium demand outstripping the supply. In addition, changing prospects of investments in palladium have also contributed to the growth of the market. Several new palladium exchange-traded funds by companies such as Absa Capital in South Africa are expected to create a significant boost for the palladium market.

Growing demand for palladium in catalytic converters in the automotive industry in vehicles exhausts are one of the major growth factors driving the palladium market. Demand for the metal from other sectors such as jewelry and industrial are also anticipated to contribute to the growth of the market. However, rising prices of palladium owing to supply issues in South Africa and declining state stockpiles in Russia are expected to hamper the growth of the market. North America was the largest consumer for palladium, followed by China owing to the presence of the vast automotive industry in the region. Future market growth is expected to be from Asia Pacific with the growing industrial activities in emerging economies such as India. These factors are expected to provide new opportunities for the growth of the market.

Source: https://www.zebvo.com/2019/11/14/sales-revenue-of-palladium-to-soar-in-the-near-future-owing-to-growing-consumer-adoption/

Tags: , , , , , , ,
Posted in All Recent Posts, New Age Metals | Comments Off on New Age Metals $NAM.ca – Sales Revenue of #Palladium to Soar in the Near Future Owing to Growing Consumer Adoption $WG.ca $XTM.ca $WM.ca $PDL.ca

American Creek $AMK.ca Treaty Creek Moves Closer to Eric Sprott’s Prediction of 10 to 20 Million Ounce $TUD.ca $SII.ca $GTT.ca $AFF.ca $SEA.ca $SA $PVG.ca

Posted by AGORACOM at 11:47 AM on Thursday, November 14th, 2019
  • 23 holes drilled in the last two years have intersected significant mineralization and dramatically increased the size of the Goldstorm deposit at Treaty Creek
  • Eric Sprott re-emphasized the potential of the project in a podcast where he stated that he is “hoping they can prove up a 20-million-ounce deposit”
https://www.sprottmoney.com/Blog/after-three-weeks-going-sideways-gold-and-silver-just-woke-up-weekly-wrap-up-october-25-2019.html

11:30 –“I still believe there’s going to be huge deposit proven up there. If we get the right environment in precious metals, which it looks like we might be getting here, people are going to start looking at these things again, and it could be very, very exciting, so…and I am, kind of, hoping that they can ultimately pull up, like, a 20 million ounce deposit there. So these stocks would prove to be very, very inexpensive”

SUMMARIZING THE 2019 PROGRAM

The Company’s JV partner, Tudor Gold’s 2019 exploration program at the Goldstorm Zone on Treaty Creek totalled 9,781.8 meters with 14 diamond drill holes. This year’s drilling program generated the best near-surface results attained to date on the project. Specifically, in addition to several hundred meters extension along strike to the northeast, the 2019 program significantly expanded the mineralized limits to the southeast, where one of the best near-surface intervals averaged 2 g/t Au over 87m, within 336 m averaging 1 g/t Au in hole GS19-52.

RESULTS OF THE FINAL 5 DRILL HOLES

  • Hole GS19-49 was drilled to 960.1 m, at -80° dip, on Section 111+00 NE next to the previously announced vertical hole GS19-48, which yielded 0.725 g/t Au over 838.5m, including an upper horizon that averaged 1.048 g/t gold Au over 328.5 m. Hole GS19-49 returned equally impressive results with a comparable 0.7 g/t Au over 826.5 m and the upper horizon averaging 1 g/t Au over 249 m 
  • Along the same section, hole GS19-52 (-50° dip at 115° azimuth) was drilled much longer than expected because the Goldstorm System continues at least 700 m to the southeast ; GS19-52 averaged 1 g/t gold over 336 meters with a higher grade core of 2 g/t gold over 87 meters within the upper horizon.

Tudor Gold Exploration Manager, Ken Konkin explained: “Clearly the results of the previously reported deep vertical step-out holes demonstrate the impressive size and grade consistency of the Goldstorm system. Within the overall mineralized package of fragmental intermediate volcanic rocks there are several sub-horizontal horizons of significantly higher gold grades. The uppermost portions of the previously reported holes GS19-42, GS19-47 and GS19-48 contained respectively, 1.268 g/t gold over 252 m, 0.828 g/t gold over 301.5 m and 1.048 g/t gold over 328.5 m. We now have several other drill holes with excellent near-surface gold values to add to this list of growing intercepts. GS19-52 has returned the highest core gold grades of 2.006 g/t Au over 87 m within a 336m intercept of 1.004 g/t Au.

These intercepts are part of the uppermost portion of the Goldstorm system which we refer to as the ‘300 Horizon’. The ‘300 Horizon’ remains open along strike to the northeast as well as to the southeast. In addition, the lower horizons of the Goldstorm system also remain open in all directions and the lowest horizon is open at depth.”

Furthermore, Mr. Konkin added: “We are seeing consistent silver and copper mineralization associated with the deeper gold horizons such as the previously reported 151.5 m zone of 0.572 g/t gold, 8.5 g/t silver and 0.21% copper that was intercepted from 665.0 to 816.5 m in GS19-47 and a 66.0 m zone with 0.958 g/t gold, 3.9 g/t silver and 0.35% copper, whichwas intercepted from 874.5 to 940.5 m in GS19-48. Similarly, we have now seen in GS19-49, a 78 m intercept averaging 1.145 g/t gold, 11.2 g/t silver and 0.21% copper (750-828 m) and in GS19-52 an 88.5 m interval averaging 0.352 g/t gold, 9.3 g/t silver and 0.25% copper (515-603.5 m). Not only does the Goldstorm Zone remain open at depth and along strike, we are now seeing base-metal associations possibly as part of a zonation within the hydrothermal system.”

The final three footwall extension holes (GS19-50, GS19-51 and GS19-53) were completed on section 110+00 NE. These were successful in extending the width of the mineralized zone to the southeast:

  • Hole GS19-50 returned an average of 0.602 g/t Au over 577.5 m including 0.811 g/t Au over 267.0 m in the ‘300 Horizon‘
  • Hole GS19-51 returned an average of 0.721 g/t Au over 246 m in the ‘300 Horizon’ and a lower horizon that averages 1.017 g/t Au over 40.5 m.
  • Hole GS19-53 returned an average of 0.984 g/t Au over 147.0 m in the ‘300 Horizon’
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/682/49176_99c64899f4a48b79_001.jpg

About American Creek

American Creek is a Canadian junior mineral exploration company with a strong portfolio of gold and silver properties in British Columbia.

Three of those properties are located in the prolific “Golden Triangle”; the Treaty Creek and Electrum joint venture projects with Tudor Gold/Walter Storm as well as the 100% owned past producing Dunwell Mine.

The Treaty Creek Project is a Joint Venture with Tudor Gold owning 60% and acting as operator. American Creek and Teuton Resources each have 20% interests in the project. American Creek and Teuton are both fully carried until such time as a Production Notice is issued, at which time they are required to contribute their respective 20% share of development costs. Until such time, Tudor is required to fund all exploration and development costs while both American Creek and Teuton have “free rides”.

More information about the Treaty Creek Project can be found here: https://americancreek.com/index.php/projects/treaty-creek/home

A drill program is also ongoing on American Creek’s 100% owned Dunwell Mine property located near Stewart. More information can be found here: https://americancreek.com/index.php/projects/dunwell-mine

The Corporation also holds the Gold Hill, Austruck-Bonanza, Ample Goldmax, Silver Side, and Glitter King properties located in other prospective areas of the province.

For further information please contact Kelvin Burton at: Phone: 403 752-4040 or Email: [email protected]. Information relating to the Corporation is available on its website at www.americancreek.com.

Hub on Agoracom
  FULL DISCLOSURE: American Creek is an advertising client of AGORA Internet Relations Corp.

Tags: , , , , , , , , , , , , , , , ,
Posted in All Recent Posts, American Creek Resources Ltd. | Comments Off on American Creek $AMK.ca Treaty Creek Moves Closer to Eric Sprott’s Prediction of 10 to 20 Million Ounce $TUD.ca $SII.ca $GTT.ca $AFF.ca $SEA.ca $SA $PVG.ca

ZEN Graphene Solutions $ZEN.ca – Reports on Multiple Intellectual Property Licensing Agreements $LLG.ca $FMS.ca $NGC.ca $CVE.ca $DNI.ca

Posted by AGORACOM at 8:26 AM on Thursday, November 14th, 2019

Thunder Bay, Ontario–(Newsfile Corp. – November 14, 2019) – ZEN Graphene Solutions Ltd. (TSXV:ZEN) (“ZEN” or the “Company“)  has signed the definitive graphene manufacturing process License Agreement referred to in a news release on May 30, 2019. This agreement licenses to ZEN the intellectual property created by scientists and laboratories within a renowned Canadian University. This agreement has no expiry date and provides that a royalty is payable by ZEN based on the annual amount of material processed under the intellectual property.

The company also reports that it has signed an 18-month exclusive initial option agreement with the University of Guelph (Guelph) for intellectual property regarding an electrochemical exfoliation (ECE) process to produce Graphene Oxide. In addition, the University of British Columbia (UBC) and ZEN have begun negotiating a Collaborative Research Agreement (CRA) template that will form the basis of each agreement with various UBC researchers. Neither Guelph nor UBC is party to the definitive agreement mentioned above.

Francis Dubé, CEO commented: “These three Canadian universities are contributing significantly to unlocking the value of the Albany Graphite deposit and creating a strong intellectual property foundation for the company. We are happy to bring investment dollars, both directly and indirectly, via various grants to these academic partners and will continue to support research opportunities in the exciting field of nanoscience.”

The definitive License Agreement took effect November 1, 2019 and subsequently ZEN has begun investing in certain equipment required under this process. ZEN anticipates that the equipment will be installed during Q1 2020 at its Guelph location thereby allowing the Company to start production of this graphene product for market development and subsequent sale.

The exclusive agreement with Guelph results from research and development by Prof. Aicheng Chen and his group. Early results from this process are very encouraging with Albany Graphite significantly outperforming both flake/sedimentary graphite and synthetic graphite, demonstrating again the uniqueness of ZEN’s graphite and its superior performance to exfoliate into graphene products.

Several researchers at UBC Okanagan continue to work with ZEN’s material in multiple areas including the synthesis of Graphene Quantum Dots and Graphene Oxide, along with multiple applications including battery anodes, polymers, aluminum, concrete, coatings, and others. Given that collaboration amongst UBC researchers is expected, this intellectual property template should accelerate the science by eliminating repetitive negotiation with each research team at UBC. ZEN will report on material final agreements with UBC as they are executed.

About ZEN Graphene Solutions Ltd.

ZEN is an emerging graphene technology solutions company with a focus on the development of graphene-based nanomaterial products and applications. The unique Albany Graphite Project provides the company with a competitive advantage in the potential graphene market as independent labs in Japan, UK, Israel, USA and Canada have independently demonstrated that ZEN’s Albany Graphite/Naturally PureTM is an ideal precursor material which easily converts (exfoliates) to graphene, using a variety of mechanical, chemical and electrochemical methods.

For further information:

Dr. Francis Dubé, Chief Executive Officer
Tel: +1 (289) 821-2820
Email: [email protected]

Tags: , , , , , , , , ,
Posted in All Recent Posts, Zen Graphene Solutions | Comments Off on ZEN Graphene Solutions $ZEN.ca – Reports on Multiple Intellectual Property Licensing Agreements $LLG.ca $FMS.ca $NGC.ca $CVE.ca $DNI.ca

Empower Clinics $CBDT.ca Reports Q3 2019 Results Highlighted by a 137% increase in clinic revenues compared to Q3 2018 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:23 AM on Thursday, November 14th, 2019
  • 5,807 patient visits generated revenue of $663,003, compared to 1,864 patient visits that generated $279,850 for Q3 2018.
  • Cash used in operating activities improved by $1,309,913 from $3,129,583 for YTD 2018, compared to $1,819,670 for YTD 2019.

VANCOUVER, Nov. 14, 2019  - EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (OTC: EPWCF) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics in the U.S., has filed today its unaudited condensed interim consolidated financial statements for the three and nine months ended September 30th, 2019 and related management’s discussion and analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated.

“Our focus on operational excellence and cost controls are key contributors to strong year-over-year growth numbers and the reduction in direct clinic expense, as we continue to serve the 165,000 patients in our database,” said Steven McAuley, Empowers Chairman & CEO. “The Company is beginning to fulfill its promise of vertical integration with the build-out of the extraction and production center in Portland, OR plus with an increased focus on our proprietary CBD product lines and diversified clinic revenues, the Company has a clear path of growth and profitability going forward.”

Q3 2019 Highlights

  • 5,807 patient visits generated revenue of $663,003, compared to 1,864 patient visits that generated $279,850 for Q3 2018.

  • Net loss of $504,531, compared to $378,657 for Q3 2018, which was primarily driven by increased revenues and fair value adjustments offset by net increased in operating expenses related to the operations of Sun Valley.

  • Cash used in operating activities improved by $1,309,913 from $3,129,583 for YTD 2018, compared to $1,819,670 for YTD 2019.

  • Cash at September 30, 2019 of $178,578, compared to $157,668 at December 31, 2018, which was primarily driven by debt and equity financings during the nine months ended September 30, 2019 and partially offset by cash used in operations, the cash investment in Sun Valley and cash investment in Sun Valley Health Franchise launch.

Highlights

  • Strategic redirection: The Company has been re-positioning its overall strategy to become a vertically integrated health and wellness brand that connects to its 165,000 patients using a data driven focus to improve patients’ lives with products, technology and health systems.

  • Experienced and Seasoned Board of Directors: The Company Board of Directors includes its CEO Steven McAuley, Dustin Klein, the Co-Founder of Sun Valley Clinics and the SVP, Business Development and Andrejs Bunkse, owner and practicing attorney of Rain Legal and Counsel to numerous cannabis enterprises in the U.S. and Canada.

  • Strategic Development: The Company has opened its first hemp-derived CBD extraction facility in greater Portland, Oregon with the first extraction system expected to have the capacity to produce 6,000 kg of extracted product per year. The Company took possession of the new extraction facility June 1st, 2019 and has been awarded it’s hemp-handlers licence from the Oregon Department of Agriculture, allowing the Company to enter the next phase of build-out and full operations in 2019. The Company expects preliminary production of its Sollievo CBD line to take place in the extraction center in 4Q 2019.

  • Strategic Partnership: The Company has entered into a Letter of Intent (“LOI”) to form a Joint Venture Partnership (“JV”) with Heritage Cannabis Holdings Corp (CSE: CANN) (“Heritage”). Terms of the LOI have Empower and Heritage each with a 50% ownership of the JV. Heritage will install extraction units and related downstream extraction equipment inside Empower’s existing licenced hemp processing facility in Sandy, Oregon. Once operational, the JV will begin producing proprietary branded products for Empower’s clinics and third party partners for distribution in the United States.

2019 Outlook and Catalysts

  • Enhanced Corporate Governance: The Company has prioritized corporate governance practices under the leadership of its Board of Directors and Chairman Steven McAuley, to ensure financial and accounting controls operate at the highest of standards.

  • Improved Capital Markets Profile: Empower is diversifying its business model to become a vertically integrated operator in the global cannabis sector with a focus on patient care, CBD product distribution, research & development and CBD product extraction. The Company believes this will appeal to a broader base of shareholders and investors and provide greater access to capital and improved trading liquidity.

  • Increased Patient Access: With a rapidly expanding company-owned clinic network and significant expansion opportunity through the Sun Valley Health franchise model, Empower anticipates it will grow its total patient list substantially in the years ahead. This is expected to provide greater opportunity for treatment analysis using artificial intelligence (AI), through progressive initiatives that include adding the Endocanna DNA test kit to the Company product & service offering in clinics and online. Ensuring the Company is a leader in understanding the efficacy of cannabis-related treatment options is an imperative.

  • Focus on CBD Product Sales: The Company has launched its online store to sell its lines of hemp-derived CBD based products and premium health & wellness supplements. Customers can purchase products, including CBD lotions, tinctures, spectrum oils, capsules, lozenges, patches, e-drinks, topical lotions, gel caps, hemp extract drops and pet-elixir hemp extract drops. Patients and customers will be able to access Sun Valley Health customer service, home delivery and e-commerce platforms.

  • Market Leading Technology: Empower utilizes market-leading patient electronic management and POS system that is HIPAA compliant and provides deep insight to patient care. The Company supports remote patients using its tele-medicine portal, enabling patients who do not live near one of its clinic locations, or are disabled or unable to come to a location, to still benefit from a doctor consultation.

  • New Modalities and Services: The Company has launched new physician based modalities and services into the Sun Valley Health clinics and has commenced booking appointments and providing the new services. Each of these services provides the opportunity for increased patient retention, higher revenue per patient visit and increased patient visits per year. The new services include:

    • Physician’s CBD Enhanced Massage, Acupuncture, or Cupping Sessions

    • CBD-Cannabis-Supplement Consumption & Coaching Consultation

    • Introduction to Alternative Health and Cannabinoid Therapies by a Physician

    • Comprehensive Naturopathic Patient Analysis & Consultation

    • Dietary Antigen Testing, Physician Consultation/Action Plan, & Concierge Blood Draw

    • Neurotransmitter (urine) Profile & Physician Consultation/Action Plan

    • Spectracell Micronutrient Test & Physician Consultation/Action Plan
  • Launches Nationwide Franchise: The Company has launched its nationwide franchise program under the Sun Valley Health brand to dramatically grow our clinic & store footprint increasing direct access to patients and to sell hemp-derived CBD products and premium wellness products directly to our customers and online at our new e-commerce store at www.sunvalleyhealth.com

Financial Summary

  $, except patient visits Three months ended September 30, Nine months ended September 30,
  2019 2018 2019 2018
Patient visits 5,807 1,864 11,304 6,293
Clinic revenues 663,003 279,850 1,406,872 894,477
Direct clinic expenses (55,397) (88,956) (177,560) (301,392)
Loss from operations (843,897) (405,048) (2,547,276) (3,716,474)
Net loss (504,531) (378,657) (2,359,579) (5,132,848)
Net loss per share (0.00) (0.01) (0.02) (0.09)

Financial Performance

Clinic revenues for Q3 2019 were $663,003, compared to Q3 2018 revenues of $279,850. This increase over the prior year is attributable to the acquisition of Sun Valley Clinics.

Direct clinic expenses for Q3 2019 were $55,397, compared to Q3 2018 direct clinic expenses of $88,956. These expenses declined despite the increase in revenues due to improved operational controls to align labor cost with direct patient consultations. The Company employs a diverse mix of physicians and practitioners.

Net loss from operations for Q3 2019 was $843,897, compared to Q3 2018 net loss of $405,048. This increase in loss over prior year is primarily attributable operating expenses increasing due to timing of recognition of the expense associated with non-cash share-based awards to management.

Net loss for Q3 2019 was $504,531, respectively, compared to Q3 2018 net loss of $378,657. This increase over prior year is primarily attributable to the increase in operating expenses as noted above, which was partially offset by gains on change in fair value of the conversion option of convertible debentures and warrants.

During Q3 2019, the Company used $1,819,670 in cash from operations after changes in non-cash working capital. The Company invested $629,636 for the acquisition of Sun Valley Clinics and raised $2,470,216 via proceeds from various issuances of shares, convertible debentures and notes.

Please refer to the Company’s unaudited condensed interim consolidated financial statements, related notes and accompanying management discussion and analysis for a full review of the operations.

ABOUT EMPOWER

Empower is a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics, operating the Sun Valley Health clinic brand www.sunvalleyhealth.com, for its nine corporate locations and for franchises in the United States. As a CBD product manufacturer under the Sollievo brand, the Company distributes its lines through clinics, online and through retail partners. Extraction operations are currently being developed in the Company’s new extraction facility in Oregon.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that the hemp-based CBD extraction facility may not be fully operational in 2019 if at all; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2019/14/c6801.html

Investors: Steve Low, Boom Capital Markets, [email protected], 647-620-5101; Investors: Steven McAuley, CEO, [email protected], 604-789-2146; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARICopyright CNW Group 2019

Tags: , , , , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Reports Q3 2019 Results Highlighted by a 137% increase in clinic revenues compared to Q3 2018 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

#Datametrex #AI Limited Fake News Filter Shows Propaganda Accounts Active in #DonCherry Scandal

Posted by AGORACOM-JC at 7:17 AM on Thursday, November 14th, 2019
  • 50,000 plus tweets we analyzed in one day, more that 30 accounts were suspicious in nature and using the issue to promote a divisive agenda.
  • A number of the accounts identified were also active in the #ELXN43 campaign buzz on social media
  • “This project further demonstrates how important it is to have tools to identify fake news sources so government, corporations and high profile individuals can control the narrative around their issues and brands,” says Marshall Gunter, CEO of the Company.

TORONTO, Nov. 14, 2019 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G) yesterday shared the results of its fake news filter on the Canadian Federal Elections ( #ELXN43 ) in coordination with our client, Defence Research and Development Canada (DRDC). Now that the tool has been built and delivered, the Company is now able to further commercialize the solution and offer it to government and enterprise clients alike. 

Out of interest, we decided to turn the filter on the recent scandal involving hockey commentator Don Cherry to see if known propaganda accounts and BOTs were active in the conversations and trying to use it as a wedge to further divide public opinion in Canada. We were not surprised to learn that of the 50,000 plus tweets we analyzed in one day, more that 30 accounts were suspicious in nature and using the issue to promote a divisive agenda. A number of the accounts identified were also active in the #ELXN43 campaign buzz on social media. 

As with the project we completed for DRDC, we used our NexaNarrative tool, for narrative tracking, disinformation detection, and publisher classification. Building on our previous fake news detection work, NexaNarrative provides narrative identification and growth tracking software that allows analysts to track the spread of disinformation online and to engage this disinformation using the BEND doctrine of information warfare currently in use by Canada and most other NATO countries.

“This project further demonstrates how important it is to have tools to identify fake news sources so government, corporations and high profile individuals can control the narrative around their issues and brands,” says Marshall Gunter, CEO of the Company.

For more information on this project or to learn how Datametrex can assist your organization in social media discovery, Fake News Filters and BOT detection please go to:

www.nexalogy.com

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

For further information, please contact:

Jeff Stevens – President
Phone: (416) 482-3282
Email: [email protected]

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: , , , , , ,
Posted in Datametrex AI Limited | Comments Off on #Datametrex #AI Limited Fake News Filter Shows Propaganda Accounts Active in #DonCherry Scandal

« Older Entries
Newer Entries »